CLINICAL TRIALS PROFILE FOR MOLNUPIRAVIR
✉ Email this page to a colleague
Clinical Trials for Molnupiravir
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT04392219 ↗ | COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers | Completed | Ridgeback Biotherapeutics, LP | Phase 1 | This is a First In Human study designed to assess the safety, tolerability and pharmacokinetics of EIDD-2801 in healthy human volunteers. |
| NCT04405570 ↗ | A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 | Completed | Ridgeback Biotherapeutics, LP | Phase 2 | This is a phase IIa, double-blind, placebo-controlled, randomized trial, designed to compare the safety, tolerability, and antiviral activity of EIDD-2801 versus placebo as measured by infectious virus detection in symptomatic adult outpatients with COVID-19 |
| NCT04405739 ↗ | The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) | Recruiting | Ridgeback Biotherapeutics, LP | Phase 2 | Designed as a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults with polymerase chain reaction (PCR)-Confirmed COVID-19. |
| NCT04575584 ↗ | Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001) | Terminated | Merck Sharp & Dohme Corp. | Phase 2/Phase 3 | This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the rate of sustained recovery through Day 29. |
| NCT04575597 ↗ | Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002) | Active, not recruiting | Merck Sharp & Dohme Corp. | Phase 2/Phase 3 | This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the percentage of participants who are hospitalized and/or die through Day 29 |
| NCT04746183 ↗ | AGILE (Early Phase Platform Trial for COVID-19) | Recruiting | Lancaster University | Phase 1/Phase 2 | The AGILE platform master protocol allows incorporation of a range of identified and yet-to-be-identified candidates as potential treatments for adults with COVID-19 into the trial. Candidates will be added into the trial via candidate-specific trial (CST) protocols of this master protocol as appendices. Having one master protocol ensures different candidates are evaluated in the same consistent manor and opening up new trials for new candidates is more efficient. Inclusion of new candidates will be determined by the AGILE Scientific Advisory Board based on pre-clinical data, evidence in the clinical setting and GMP capabilities. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Molnupiravir
Condition Name
Clinical Trial Locations for Molnupiravir
Trials by Country
Clinical Trial Progress for Molnupiravir
Clinical Trial Phase
Clinical Trial Sponsors for Molnupiravir
Sponsor Name
